Pre-Made Epoetin Alfa biosimilar, Recombinant Protein: Recombinant EPO(erythropoietin) therapeutic protein targeting EPOR for drug discovery and mechanism of action (MOA) research

Pre-Made Epoetin Alfa biosimilar, Recombinant Protein: Recombinant EPO(erythropoietin) therapeutic protein targeting EPOR is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[3] Authorised by the European Medicines Agency on 28 August 27, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.

Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-840-1mg	1mg	3090
GMP-Bios-INN-840-10mg	10mg	Inquiry
GMP-Bios-INN-840-100mg	100mg	Inquiry
GMP-Bios-INN-840-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Epoetin Alfa biosimilar, Recombinant Protein: Recombinant EPO(erythropoietin) therapeutic protein targeting EPOR
INN Name	Epoetin Alfa
Target	EPOR
Format	Recombinant Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	EPO
VD LC	EPO
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Centocor Ortho Biotech Products LP (Raritan NJ USA) / Amgen (Thousand Oaks CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0